RCM
VNDA icon

Riverhead Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Riverhead Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$80K Buy
6,000
+300
+5% +$4.18K ﹤0.01% 1374
2019
Q2 		$80K Buy
5,700
+100
+2% +$1.59K ﹤0.01% 1386
2019
Q1 		$103K Hold
5,600
– – ﹤0.01% 1326
2018
Q4 		$146K Buy
+5,600
New +$132K 0.01% 1194

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Riverhead Capital Management's VNDA Position: Q3 2019 in Review

Riverhead Capital Management increased its Vanda Pharmaceuticals (VNDA) stake by 5.3% in Q3 2019, buying an estimated $4.18K and bringing the position to 6,000 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Riverhead Capital Management first reported a position in VNDA in Q4 2018 and has held it in 4 quarters since. The position peaked at $146K in Q4 2018. 168 funds tracked by Wall St. Rank hold VNDA as of Q3 2019.

  • Riverhead Capital Management held 6,000 shares of Vanda Pharmaceuticals worth $80K as of Q3 2019.
  • Riverhead Capital Management bought 300 Vanda Pharmaceuticals shares in Q3 2019, an estimated $4.18K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1374 holding.
  • Riverhead Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2018 and has held it in 4 quarters since.
  • Riverhead Capital Management's Vanda Pharmaceuticals position peaked at $146K in Q4 2018.
  • 168 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.